GH-fragment design
The peptide reproduces the C-terminal segment of growth hormone with a stabilizing substitution, separating it from the full hormone’s wider receptor effects.
Back to Peptide Library
Growth Hormone Fragment
AOD-9604
Anti-Obesity Drug 9604 • Stabilized HGH Fragment 176–191 Analog
AOD-9604 was developed to isolate the fat-metabolism activity of a growth-hormone fragment. Its clinical safety record is more substantial than most research peptides, but the largest obesity trial did not show significant weight loss versus placebo.
At a glance
AOD-9604 Quick Reference
- Community dose
- Members onlySign in to view dosing details.
- Higher community dose
- Members onlySign in to view dosing details.
- Cycle
- Members onlySign in to view dosing details.
- Clinical evidence
- Oral trialsObesity program did not establish efficacy
Overview
What Is AOD-9604?
AOD-9604 stands for Anti-Obesity Drug 9604. It is a stabilized, 16-amino-acid synthetic analog of the tail end of human growth hormone. Researchers developed it to test whether the fragment could influence fat metabolism without the broader growth and IGF-1 effects of full growth hormone.
It moved through six human trials involving about 900 adults. The pooled safety report found it generally well tolerated, with no consistent signal of increased IGF-1 or impaired carbohydrate metabolism. Those trials mainly investigated oral formulations; they do not directly validate today’s community SubQ protocol.
The key outcome is less encouraging: the largest obesity study did not show a statistically significant weight-loss benefit over placebo. Development for obesity was discontinued. AOD-9604 is related to HGH Fragment 176–191 sold elsewhere, but the stabilized analog and the unmodified fragment are not identical compounds.
Mechanism
AOD-9604 Mechanism of Action
Fat-metabolism hypothesis
Preclinical research explored increased lipolysis and reduced lipogenesis. These mechanisms did not translate into a demonstrated weight-loss benefit in the largest obesity trial.
Growth signaling
The pooled human studies did not find a consistent rise in IGF-1 or disruption of glucose measures at studied doses and formulations.
Route gap
Most clinical exposure was oral. Effects or tolerability after repeated community SubQ dosing cannot be assumed to match those results.
Research findings
AOD-9604 Benefits
The most useful established human finding is tolerability in the studied formulations. Proposed fat-loss and cartilage applications need stronger evidence.
Clinical Tolerability
A pooled review of six trials covering 893 adults found AOD-9604 generally well tolerated in the doses and formulations studied.
IGF-1 Measures
The clinical safety analysis did not identify a consistent IGF-1 increase, a key distinction from full growth hormone exposure.
Carbohydrate Metabolism
The published safety analysis did not show a clear adverse effect on glucose handling during the studied courses.
Weight-Loss Outcome
The largest obesity trial did not establish meaningful weight loss versus placebo; a positive mechanistic idea is not the same as clinical efficacy.
Cartilage Models
Animal work has explored cartilage effects, including combinations with hyaluronic acid. This is not a proven joint treatment in people.
Community Use
Some users report a subtle extra edge during a cut when nutrition and training are already consistent; attribution is difficult.
Protocol planning
AOD-9604 Dosing Protocol
Members Access Only
Sign in or create a free account to view this content.
Preparation
AOD-9604 Reconstitution
AOD-9604 can gel or aggregate during preparation. The acid-first example below uses dilute acetic acid followed by BAC water.
Reconstitution Example
5mg vial + 0.5mL 0.6% acetic acid + 2mL bacteriostatic water
Result2mg/mL
Reconstitution steps
1
Prepare
Wash your hands, clean the work surface, and wipe vial stoppers with alcohol. Allow them to dry.
2
Add the compatible acid solution first
For this example, add 0.5mL of 0.6% acetic acid slowly down the inside wall of the vial.
3
Add bacteriostatic water
Add 2mL slowly down the vial wall. Do not spray directly onto the powder.
4
Dissolve gently
Let the contents dissolve; roll or swirl gently if needed. Do not shake.
5
Storage
Store refrigerated at 2–8°C (36–46°F) and away from light when the product instructions support this. Record the reconstitution date in your research journal.
N=1 reports
AOD-9604 Community Experience
Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.
Positive Reports
- Some users describe a subtle change in waist or lower-abdominal fat after several weeks of consistent nutrition and training.
- Users who already track a cut sometimes view it as a small adjunct rather than a standalone driver.
- Morning use is common because it fits existing fasting or training routines.
Negative & Mixed Reports
- Many users report no noticeable change.
- Gelling, clumping, and visible aggregation recur in preparation reports.
- Diet, exercise, and concurrent compounds make subtle effects especially hard to attribute to AOD-9604.
Stacking & synergy
AOD-9604 Stacking & Synergy
These pairings come from community practice and mechanism, not controlled AOD-9604 combination trials.
AOD-9604 + Tirzepatide
Tirzepatide is the primary weight-loss driver in this pairing. AOD-9604 is discussed as an add-on when a cut has already slowed, but its incremental effect is unmeasured.
AOD-9604 + Retatrutide
These act through different proposed pathways, yet there is no trial showing that AOD-9604 adds measurable loss to retatrutide.
AOD-9604 + CJC-1295/Ipamorelin
A secretagogue already stimulates endogenous GH release, making the rationale for an added GH fragment less compelling and harder to evaluate.
AOD-9604 + Tesamorelin
Tesamorelin has its own GH-axis effects; there is no evidence that adding AOD-9604 improves the result.
Safety notes
AOD-9604 Side Effects & Safety
The published human safety data are relatively extensive for a research peptide, but they mainly concern studied oral and intravenous formulations. They do not establish long-term SubQ safety or efficacy for a retail vial.
Clinical Observations
- In the pooled trials, overall adverse-event patterns were similar to placebo.
- No consistent increase in IGF-1 or clinically important carbohydrate-metabolism signal was identified.
- The studied populations and formulations limit how far those findings can be generalized.
Practical & Unknown Risks
- Community reports mention injection-site irritation, occasional headache, nausea, and preparation problems.
- Visible gelling or aggregation raises product-quality and dosing concerns.
- Long-term repeated SubQ exposure and use in pregnancy or cancer contexts remain poorly studied.
AOD-9604 Precautions
Do Not Use If You Have
- Known hypersensitivity to AOD-9604 or any formulation ingredient.
- Pregnancy or breastfeeding, where safety data are absent.
- A tested-sport obligation: AOD-9604 is prohibited on the WADA list.
Use Caution With
- An active or past cancer diagnosis without clinician guidance.
- Other GH-axis compounds, where overlapping effects and attribution complicate assessment.
- A vial that gels, clumps, or has unverified preparation instructions.
AOD-9604 is not FDA approved for weight loss or any other indication and is prohibited by WADA as a growth-hormone fragment.
Final verdict
Peptide Protocols Verdict on AOD-9604
Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.
Our opinionated opinion
AOD gets written off constantly. “It doesn’t work.” “It gelled.” “I felt nothing.” The largest obesity trial missed the weight-loss endpoint, and we would never present it as the main reason someone loses fat. That part of the criticism is fair.
The rest of it usually is not. We see AOD as a fat-mobilization add-on. By itself, the results we have seen are weak. People run it like a standalone fat-loss drug, eat whenever they want, and then decide the peptide failed. The protocol associated with the results we have seen is narrower than that.
In our experience, it needs a pairing. Retatrutide or something in that class is the obvious one. Our rationale is fat mobilization alongside an existing deficit; AOD does not create that deficit on its own. The approach we have used is morning administration while fasted, followed by another two to three hours with water only. That fasting window is central to how we have evaluated it. We suspect inconsistent fasting explains some disappointing reports, but we cannot establish that eating wastes a dose or that fasting determines efficacy.
Fasted training is the version we have found most interesting. The idea is to pair the proposed lipolytic effect with exercise demand. We have seen visible changes in stubborn fat in people who had stalled on Reta alone, although those observations cannot isolate AOD from training, intake, or the rest of the stack.
It is still not a primary. The human weight-loss data is weak; the largest obesity trial was oral, earlier studies also used IV administration, and the community is using it subcutaneously. Track waist, the scale, and the rest of the stack before you credit it. The published oral tolerability findings are part of why we remain interested, but they do not establish SubQ or combination safety. Used the way most people use it, we think it is a waste. Used fasted, paired, and timed, it is one of the few add-ons where we have seen something visible when the main compound plateaued.